Back to Journals » Biologics: Targets and Therapy » Volume 2 » Issue 4

The insulin-like growth factor system and its receptors: A potential novel anticancer target

Authors Lindsay CR, Evans TRJ

Published 5 December 2008 Volume 2008:2(4) Pages 855—864

DOI https://doi.org/10.2147/BTT.S3841

Review by Single-blind

Peer reviewer comments 3

Colin R. Lindsay1, T R Jeffry Evans1,2

1Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; 2University of Glasgow, CR-UK Beatson Laboratories, Garscube Estate, Glasgow, United Kingdom

Abstract: The current generation of novel anticancer therapies that are in preclinical and clinical development are based on exploiting our increasing understanding of the molecular and cellular basis of cancer development and progression. Accelerated rates of cell division and proliferation have been postulated to predispose to the development of malignant disease. The insulin-like growth factor (IGF) signaling system has an important physiological role in regulating cellular proliferation and apoptosis. This function has led to considerable interest in its relevance to neoplasia over the last decade. In this review, we give an overview of the IGF system physiology, discuss the epidemiological significance of IGF signaling and neoplasia, and review the preclinical and clinical studies in targeting IGF receptors as cancer therapies.

Keywords: insulin, growth factor, IGF-1, clinical trials

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]